Want to see AU:ADO full AI Analyst Report?
ADO Stock Chart & Stats
AU$0.02
>-AU$0.01(>-0.01%)
At close: 4:00 PM EDT
AU$0.02
>-AU$0.01(>-0.01%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume2.78M
Average Volume (3M)1.47M
Market Cap
AU$71.71M
Enterprise ValueAU$99.20M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$2.85M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,259,767,300
10 Day Avg. Volume1,501,441
30 Day Avg. Volume1,471,917
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.79
Price to Sales (P/S)35.07
P/FCF Ratio-5.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$2.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Surface-chemistry TechnologyAnteoTech’s proprietary surface-functionalisation platform is a structural competitive asset: it underpins multiple product applications (diagnostics, biosensors, battery materials) and creates technical barriers to entry. Over 2–6 months this supports recurring product sales, licensing opportunities and partner validation as customers integrate materials into workflows.
Diversified Commercial Revenue StreamsA multi-channel monetisation model (product sales, licensing, paid development and grants) reduces reliance on any single revenue source and smooths long-term cash inflows as different commercialisation pathways mature. This structural diversity improves the company’s ability to monetise IP across diagnostics and energy markets as adoption cycles vary.
Manageable LeverageA debt-to-equity around 0.62 implies the company is not overlevered relative to peers, preserving flexibility to fund commercialization or R&D over the medium term. Manageable leverage reduces immediate refinancing risk and gives management options (capex, partnerships, selective borrowing) while technologies progress toward scale.
Bears Say
Persistent Losses And Negative MarginsSustained unprofitability constrains retained earnings and forces reliance on external funding for operations and growth. Over several months this limits reinvestment, can dilute shareholders via capital raises, and weakens measured returns (negative ROE), reducing the company’s financial resilience as it scales commercial adoption.
Extreme Revenue Volatility And Steep Recent DeclineSevere revenue swings and very large recent declines indicate fragile customer traction or lumpy partner payments. Structurally, this increases forecasting uncertainty, complicates investment decisions, and can delay qualification cycles with partners, slowing the steady revenue ramp required to convert technological advantage into durable commercial cashflows.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow create persistent funding needs and heighten dependence on equity or debt raises. Over a 2–6 month horizon this constrains ability to scale manufacturing or support customer qualification activities, raises execution risk, and can reduce negotiating leverage with partners and suppliers.
AnteoTech Ltd News
ADO FAQ
What was AnteoTech Ltd’s price range in the past 12 months?
AnteoTech Ltd lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is AnteoTech Ltd’s market cap?
AnteoTech Ltd’s market cap is AU$71.71M.
When is AnteoTech Ltd’s upcoming earnings report date?
AnteoTech Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 21 days.
How were AnteoTech Ltd’s earnings last quarter?
AnteoTech Ltd released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is AnteoTech Ltd overvalued?
According to Wall Street analysts AnteoTech Ltd’s price is currently Overvalued.
Does AnteoTech Ltd pay dividends?
AnteoTech Ltd does not currently pay dividends.
What is AnteoTech Ltd’s EPS estimate?
AnteoTech Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnteoTech Ltd have?
AnteoTech Ltd has 3,259,767,300 shares outstanding.
What happened to AnteoTech Ltd’s price movement after its last earnings report?
AnteoTech Ltd reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of AnteoTech Ltd?
Currently, no hedge funds are holding shares in AU:ADO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnteoTech Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ADO Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$86.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-58.00%
Trailing 12-Months
Company Description
AnteoTech Ltd
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Technical Analysis
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Proteomics International Laboratories Ltd.
―
Radiopharm Theranostics Limited
―